Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Accenture
Medtronic
US Department of Justice
Merck
Chinese Patent Office
Federal Trade Commission
Healthtrust
Farmers Insurance
McKinsey

Generated: December 10, 2017

DrugPatentWatch Database Preview

Bausch And Lomb Company Profile

« Back to Dashboard

What is the competitive landscape for BAUSCH AND LOMB, and what generic alternatives to BAUSCH AND LOMB drugs are available?

BAUSCH AND LOMB has seventy-five approved drugs.

There are twenty-two US patents protecting BAUSCH AND LOMB drugs.

There are one hundred and forty-four patent family members on BAUSCH AND LOMB drugs in twenty-two countries and forty-nine supplementary protection certificates in eleven countries.

Summary for Bausch And Lomb

International Patents:144
US Patents:22
Tradenames:64
Ingredients:53
NDAs:75
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Bausch And LombALAWAYketotifen fumarateSOLUTION/DROPS;OPHTHALMIC021996-002Feb 11, 2015OTCYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Bausch And LombSULTEN-10sulfacetamide sodiumSOLUTION/DROPS;OPHTHALMIC087818-001Feb 3, 1983DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Bausch And LombDORZOLAMIDE HYDROCHLORIDEdorzolamide hydrochlorideSOLUTION/DROPS;OPHTHALMIC090143-001Jun 25, 2009ATRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Bausch And LombBACITRACIN ZINC AND POLYMYXIN B SULFATEbacitracin zinc; polymyxin b sulfateOINTMENT;OPHTHALMIC064046-001Jan 26, 1995ATRXNoYes► Subscribe► Subscribe► Subscribe► Subscribe
Bausch And LombALBUTEROL SULFATEalbuterol sulfateSOLUTION;INHALATION075358-001Mar 29, 2000DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Bausch And LombPROLENSAbromfenac sodiumSOLUTION/DROPS;OPHTHALMIC203168-001Apr 5, 2013RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Bausch And LombNEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDINgramicidin; neomycin sulfate; polymyxin b sulfateSOLUTION/DROPS;OPHTHALMIC064047-001Jan 31, 1996ATRXNoYes► Subscribe► Subscribe► Subscribe► Subscribe
Bausch And LombOPCONnaphazoline hydrochlorideSOLUTION/DROPS;OPHTHALMIC087506-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Bausch And LombHYDROCORTISONE AND ACETIC ACIDacetic acid, glacial; hydrocortisoneSOLUTION/DROPS;OTIC040097-001Oct 31, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Bausch And Lomb IncIPRATROPIUM BROMIDEipratropium bromideSOLUTION;INHALATION075835-001Oct 15, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Bausch And Lomb

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And LombLOTEMAXloteprednol etabonateSUSPENSION/DROPS;OPHTHALMIC020583-001Mar 9, 1998► Subscribe► Subscribe
Bausch And LombZYLETloteprednol etabonate; tobramycinSUSPENSION/DROPS;OPHTHALMIC050804-001Dec 14, 2004► Subscribe► Subscribe
Bausch And LombVITRASERTganciclovirIMPLANT;IMPLANTATION020569-001Mar 4, 1996► Subscribe► Subscribe
Bausch And LombBESIVANCEbesifloxacin hydrochlorideSUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 2009► Subscribe► Subscribe
Bausch And Lomb IncLOTEMAXloteprednol etabonateGEL;OPHTHALMIC202872-001Sep 28, 2012► Subscribe► Subscribe
Bausch And LombZYLETloteprednol etabonate; tobramycinSUSPENSION/DROPS;OPHTHALMIC050804-001Dec 14, 2004► Subscribe► Subscribe
Bausch And LombLOTEMAXloteprednol etabonateSUSPENSION/DROPS;OPHTHALMIC020583-001Mar 9, 1998► Subscribe► Subscribe
Bausch And LombZYLETloteprednol etabonate; tobramycinSUSPENSION/DROPS;OPHTHALMIC050804-001Dec 14, 2004► Subscribe► Subscribe
Bausch And Lomb IncXIBROMbromfenac sodiumSOLUTION/DROPS;OPHTHALMIC021664-001Mar 24, 2005► Subscribe► Subscribe
Bausch And LombLOTEMAXloteprednol etabonateSUSPENSION/DROPS;OPHTHALMIC020583-001Mar 9, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BAUSCH AND LOMB drugs

Drugname Dosage Strength Tradename Submissiondate
bepotastine besilateOphthalmic Solution1.5%BEPREVE9/9/2013
bromfenac sodiumOphthalmic Solution0.07%PROLENSA7/26/2013
timolol maleateOphthalmic Solution0.5%ISTALOL10/19/2012

Non-Orange Book Patents for Bausch And Lomb

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,497,304Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid► Subscribe
8,252,307Method for treating and/or preventing retinal diseases with sustained release corticosteroids► Subscribe
7,056,893Topical treatment for prevention of ocular infections► Subscribe
6,307,052 Acid-addition salts of optically active piperidine compound and process for producing the same► Subscribe
7,282,589Acid addition salt of optically active piperidine compound and process for preparing the same► Subscribe
7,749,970Topical treatment of prevention of ocular infections► Subscribe
8,883,825Aqueous liquid preparations and light-stabilized aqueous liquid preparations► Subscribe
6,569,443 Topical treatment or prevention of ocular infections► Subscribe
7,732,415Topical treatment or prevention of ocular infections► Subscribe
6,239,113 Topical treatment or prevention of ocular infections► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Bausch And Lomb Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)9832421► Subscribe
Germany122011100019► Subscribe
World Intellectual Property Organization (WIPO)9829409► Subscribe
China1098262► Subscribe
European Patent Office0969812► Subscribe
Japan5518928► Subscribe
Australia3920300► Subscribe
World Intellectual Property Organization (WIPO)2010051291► Subscribe
Spain2371340► Subscribe
China1446812► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Bausch And Lomb Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00017Denmark► SubscribePRODUCT NAME: TOBRAMYCIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/10/652/001-003 20110720
C/GB11/054United Kingdom► SubscribePRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523
C/GB97/014United Kingdom► SubscribePRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216
2016 00031Denmark► SubscribePRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
/1999Austria► SubscribePRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306
678Luxembourg► SubscribePRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725
C0040Belgium► SubscribePRODUCT NAME: ALATROFLOXACIN; NAT. REGISTRATION NO/DATE: EU/1/98/060/001 19980327; FIRST REGISTRATION: CH 54484 19980327
C0031France► SubscribePRODUCT NAME: BROMFENAC, SES SELS OU HYDRATES PHARMACOLOGIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/11/692/001 DU 20110518; REGISTRATION NO/DATE AT EEC: EU/1/11/692/001 DU 20110518
00494Netherlands► SubscribePRODUCT NAME: BROMFENAC, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF HYDRAAT; REGISTRATION NO/DATE: EU/1/11/692/001 20110518
138Luxembourg► SubscribePRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Farmers Insurance
McKinsey
Dow
Merck
Cerilliant
Daiichi Sankyo
Fuji
Cantor Fitzgerald
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot